次世代型“包括的がん緩和医療”への取り組み—抗がん剤による耐性獲得及びがん増悪化の分子理解

DOI Web Site Web Site PubMed 参考文献15件 オープンアクセス

書誌事項

タイトル別名
  • Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer
  • Symposium Review 次世代型"包括的がん緩和医療"への取り組み : 抗がん剤による耐性獲得及びがん増悪化の分子理解
  • Symposium Review ジセダイガタ"ホウカツテキ ガン カンワ イリョウ"ヘ ノ トリクミ : コウガンザイ ニ ヨル タイセイ カクトク オヨビ ガン ゾウ アッカ ノ ブンシ リカイ

この論文をさがす

抄録

 Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. However, the application of gefitinib is ultimately limited by the emergence of mutations and other molecular mechanisms conferring drug resistance. Furthermore, it has been considered that acquired resistance to gefitinib is associated with a clinically significant risk of accelerated disease progression. We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. Using HCC827GR, we found that the inhibition of adenosine A2a receptors of NSCLC regulated cancer proliferation and exacerbation, indicating that adenosine A2a receptors may be new targets for a novel strategy in NSCLC therapy. These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 136 (5), 699-703, 2016-05-01

    公益社団法人 日本薬学会

参考文献 (15)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ